The ZBTB17 antibody is a crucial tool for studying the ZBTB17 protein, a member of the zinc finger and BTB/POZ domain-containing (ZBTB) family. ZBTB17. also known as MYC-interacting zinc finger protein 1 (MIZ1) or zinc finger protein 151 (ZNF151), functions as a transcription regulator with dual roles in gene activation and repression. Structurally, it contains an N-terminal BTB/POZ domain for protein-protein interactions and C-terminal zinc finger motifs for DNA binding. ZBTB17 is implicated in diverse cellular processes, including cell cycle control, apoptosis, and differentiation, often through interactions with oncoproteins like MYC. While MYC-ZBTB17 complexes typically repress target genes, ZBTB17 alone may activate growth-inhibitory pathways, highlighting its context-dependent role in cancer biology.
Antibodies targeting ZBTB17 enable detection and quantification of its expression in tissues or cultured cells via techniques like Western blot, immunohistochemistry, and immunofluorescence. They are essential for investigating ZBTB17's nuclear localization, protein interactions, and dysregulation in diseases such as malignancies, immune disorders, and developmental syndromes. Commercial ZBTB17 antibodies are typically raised in rabbits or mice using immunogenic peptide sequences, with validation in knockout controls to ensure specificity. Researchers utilize these tools to explore ZBTB17's tumor-suppressive or oncogenic functions, epigenetic regulation mechanisms, and therapeutic potential in precision medicine.